Systematic review of efficacy and safety of shorter regimens for drug-resistant tuberculosis (DR-TB) in children
Abstract
Introduction Recent years have witnessed the emergence of antimicrobial-resistant strains of Mycobacterium tuberculosis , resulting in drug-resistant tuberculosis (DR-TB). DR-TB is difficult to treat, necessitating prolonged therapy with multiple medications. However, attempts have been made to shorten the therapeutic regimen in DR-TB. Objective This systematic review was undertaken to investigate the efficacy and safety of short-term regimens (STRs) for the treatment of DR-TB in children. Methods We conducted a comprehensive literature search across PubMed, EMBASE, Scopus, CINHAL, Web of Science, Cochrane Library, major trial registries, and grey literature. We searched for randomized controlled trials, and observational studies, comparing World Health Organization (WHO) approved treatment regimens of ≤12 months duration (shorter regimens) versus >12 months duration (longer regimens), in children (<18 years) diagnosed with DR-TB. Data on cure rate, mortality rate, and adverse events were analyzed. Results From 44,532 records, step-wise screening of titles and abstract identified 90 potentially relevant publications. Full-text screening eliminated 13 (being reviews, reports, oral presentations, or abstracts). Among the remaining 77 (17 RCTs and 60 observational studies), in 21 studies the population did not match the review question, in 33, the intervention was different, and in 23 studies, data on children could not be extracted separately from adults. Thus this systematic…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.